stock price

The company's shares grew 28 percent in September after it terminated a licensing deal with BioMérieux and regained control of certain intellectual property.

CareDx led the Index for the month — the firm's shares rose 81 percent on the strength of its second quarter earnings report.

Proceeds from the offering, expected to close on or about Aug. 14, could be used to fund acquisitions, to repay existing debts, or for working capital.

Natera led the Index for the second month in a row after it announced that it intended to raise $75 million in a public stock offering.

Natera led the Index with a 61 percent increase in stock price, driven by the firm's announcement that it was entering the transplantation market.

The study solidified how doctors should interpret and act upon an intermediate result from the breast cancer risk test in how to treat early-stage patients.

Though the Dow, the Nasdaq, and the Nasdaq Biotechnology Index all rose in May, they were outperformed by the GenomeWeb Index.

Positive first quarter earnings reports lifted many stocks of life science tools firms even as the broader biotechnology market suffered.

The decline matched the struggles of the broader stock market, though bright spots could be found with GenMark, Quidel, and NanoString all having good months.

The firm increased the number of shares it was offering after its stock price fell sharply this week.

Pages

This year's Breakthrough Prize winners include a pair that developed a therapy for spinal muscular atrophy.

The New York Times reports on how white supremacists misconstrue genetic research, concerning many geneticists.

Researchers find that people's genetics influence their success at university, but that it is not the only factor.

In Nature this week: approach to identify genetic variants that affect trait variability, application of read clouds to microbiome samples, and more.